Our Vision
Our research goal is to understand the molecular mechanisms underlying human diseases caused by genetic mutations, with a special emphasis on inherited eye diseases. With these mechanistic insights, we develop novel and specific therapeutics by utilizing high-throughput drug screening approaches.
Our Team
- Dr. Moshe Giladi - Lab PI, Physician, Internal Medicine D;Dept. of Physiology and Pharmacology
- Dr. Yoni Haitin, Ph.D. Dept. of Physiology and Pharmacology, Tel Aviv University.
Research
of DHDDS-related retinitis pigmentosa
Retinitis pigmentosa (RP) is the most common inherited form of retinal degeneration, ultimately leading to blindness. Despite the major advancements in elucidating the genetic causes for RP, it remains incurable to date. In recent years, a growing number of disease-causing mutations in DHDDS were identified, leading to diverse clinical presentations including RP and severe neurological diseases. We have determined the atomic-resolution structure of the enzymatic complex in which DHDDS is involved and use this information to investigate its function in health and disease, as well as to develop targeted therapies for RP.
translational protein modifications
Post-translational protein modifications (PTM) are crucial for protein folding, function, and cellular localization in every cell in the human body. These modifications were highlighted in cancerous transformation, metastasis, and response to treatments. However, no specific treatments targeting aberrant PTM are currently available for clinical use. By studying key enzymes involved in the synthesis of moieties for PTM, we use a structure-guided approach to develop novel and specific cancer therapies.
Highlight Publications